Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wu, Quan ^a   Cheng, Zhongyi ^b   Zhu, Jun ^c   Xu, Weiqing ^a   Peng, Xiaojun ^c   Chen, Chuangbin ^c   Li, Wenting ^a   Wang, Fengsong ^a   Cao, Lejie ^a   Yi, Xingling ^c   Wu, Zhiwei ^a   Li, Jing ^a   Fan, Pingsheng ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c Jingjie PTM Biolabs (Hangzhou) Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PROTEIN BINDING; PROTEOME; VORINOSTAT;

ACETYLATION; CLUSTER ANALYSIS; DRUG EFFECTS; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE; UBIQUITINATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CLUSTER ANALYSIS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY; UBIQUITINATION;

EID: 84926344745     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09520     Document Type: Article

References (40)

1. Minucci, S., Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51 (2006).
2. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299 (2002).
3. Chuang, D. M., Leng, Y., Marinova, Z., Kim, H. J., Chiu, C. T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32, 591-601 (2009).
4. Dokmanovic, M., Clarke, C., Marks, P. A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5, 981-989 (2007).
5. Bolden, J. E., Peart, M. J., Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006).
6. Xu, W. S., Parmigiani, R. B., Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26, 5541-5552 (2007).
7. Petruccelli, L. A. et al. Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosis. Mol. Cancer Ther. 12, 1591-1604 (2013).
8. Johnson, A. A., Sarthi, J., Pirooznia, S. K., Reube, W. &Elefant, F. Increasing Tip60 HATlevels rescues axonal transport defects and associated behavioral phenotypes in a Drosophila Alzheimer's disease model. J. Neurosci. 33, 7535-7547 (2013).
9. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265 (2011).
10. Olsen, E. A. et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25, 3109-3115 (2007).
11. Komatsu, N. et al. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol. Rep. 15, 187-191 (2006).
12. Lee, E. et al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int. J. Mol. Med. 24, 45-50 (2009).
13. Wu, Q. et al. SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells. J. Proteome Res. 12, 4064-4073 (2013).
14. Chiu, H. W. et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS One 8, e76340 (2013).
15. Munster, P. N. et al. The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells. Cancer Res. 61, 8492-8497 (2001).
16. Bali, P. et al. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res. 11, 6382-6389 (2005).
17. Konstantinopoulos, P. A., Wilson, A. J., Saskowski, J., Wass, E., Khabele, D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol. Oncol. 133, 599-606 (2014).
18. Chen, M. Y. et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 117, 4424-4438 (2011).
19. Dasari, A. et al. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and nonsmall cell lung cancer. Invest. New Drugs 31, 115-125 (2013).
20. Jones, D. R. et al. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer. J. Thorac. Oncol. 7, 1683-1690 (2012).
21. Imre, G., Gekeler, V., Leja, A., Beckers, T., Boehm, M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res. 66, 5409-5418 (2006).
22. Desai, D., Das, A., Cohen, L., el-Bayoumy, K., Amin, S. Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res. 23, 499-503 (2003).
23. Sardiu, M. E. et al. SAHA Induced Dynamics of a Human Histone Deacetylase Protein Interaction Network. Mol. Cell. Proteomics, 13(11), 3114-3125 (2014).
24. Xu, G. et al. SAHA Regulates Histone Acetylation, Butyrylation, and Protein Expression in Neuroblastoma. J. Proteome Res. 13, 4211-4219 (2014).
25. Wilkinson, K. D. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin. Cell Dev. Biol. 11, 141-148 (2000).
26. Caron, C., Boyault, C., Khochbin, S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 27, 408-415 (2005).
27. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840 (2009).
28. Munday, D. C., Hiscox, J. A., Barr, J. N. Quantitative proteomic analysis of A549 cells infected with human respiratory syncytial virus subgroup B using SILAC coupled to LC-MS/MS. Proteomics 10, 4320-34 (2010).
29. Park, J. E. et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol. Cell. Proteomics 9, 1085-99 (2010).
30. Kim, J. Y. et al. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc. Natl. Acad. Sci. U. S. A. 110, 12414-9 (2013).
31. Trotman, L. C. et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128, 141-156 (2007).
32. Haglund, K., Dikic, I. Ubiquitylation and cell signaling. EMBO J. 24, 3353-3359 (2005).
33. Ben-Neriah, Y. Regulatory functions of ubiquitination in the immune system. Nat. Immunol. 3, 20-26 (2002).
34. Hunter, T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol. Cell 28, 730-738 (2007).
35. Sun, L., Chen, Z. J. The novel functions of ubiquitination in signaling. Curr. Opin. Cell Biol. 16, 119-126 (2004).
36. Pan, Z. et al. Systematic analysis of the in situ crosstalk of tyrosine modifications reveals no additional natural selection on multiply modified residues. Sci. Rep. 4, 7331; DOI:10. 1038/srep07331 (2014).
37. Trinidad, J. C. et al. Global Identification and Characterization of Both OGlcNAcylation and Phosphorylation at the Murine Synapse. Mol. Cell. Proteomics 11, 215-229 (2012).
38. Gray, V. E., Liu, L., Nirankari, R., Hornbeck, P. V., Kumar, S. Signatures of Natural Selection on Mutations of Residues with Multiple Posttranslational Modifications. Mol. Biol. Evol. 31, 1641-1645 (2014).
39. Udeshi, N. D. et al. Refined preparation and use of anti-diglycine remnant (Kepsilon-GG) antibody enables routine quantification of 10, 000 s of ubiquitination sites in single proteomics experiments. Mol. Cell. Proteomics 12, 825-831 (2013).
40. Yang, W. et al. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J. Proteome Res. 9, 3073-82 (2010).